“The Danish Well being Authority has concluded that the advantages of utilizing the Covid-19 vaccine from Johnson & Johnson don’t outweigh the danger of inflicting the attainable hostile impact, Vaccine-induced Thrombotic Thrombocytopenia (VITT), in those that obtain the vaccine. Subsequently, the Danish Well being Authority will proceed the Danish mass vaccination programme towards Covid-19 with out the Covid-19 vaccine from Johnson & Johnson,” learn an announcement by Denmark’s well being authority, reported Euronews.
Earlier, Denmark had additionally dropped AstraZeneca’s vaccine over considerations of “uncommon” however “severe” unintended effects. The choice was not a straightforward one to make.
“Taking the current state of affairs in Denmark under consideration, what we’re presently dropping in our effort to stop extreme sickness from Covid-19 can’t outweigh the danger of inflicting attainable unintended effects within the type of extreme blood clots in these we vaccinate,” the assertion stated.
The well being authority added that the choice “will considerably have an effect on” the vaccination rollout for individuals aged between 20 and 39, which might be delayed by as much as 4 weeks.
“The remaining goal teams will expertise a delay of about one week, as we might be getting massive quantities of different vaccines,” learn the assertion.
“This choice will, in fact, have penalties for individuals who now have their vaccination postponed. For instance, they should wait longer for the corona passport that so many people are trying ahead to getting. Age is the primary threat issue for extreme sickness from Covid-19, and these are youthful residents who will not be susceptible to turning into severely unwell,” it stated.
As of Could 1, greater than 1.3 million of the nation’s 5.8 million inhabitants had acquired a minimum of one dose of the vaccine, in line with Our World in Information.
The Johnson & Johnson vaccine, referred to as Janssen, in March grew to become the fourth jab to be permitted to be used throughout the European Union by the European Medicines Agency (EMA) after Pfizer/BioNTech, AstraZeneca/Oxford College and Moderna, reported Euronews.
However the American pharmaceutical delayed its deliveries to the 27-member bloc after stories of great blood clots emerged within the US the place greater than 6.8 million individuals have acquired a minimum of one shot.
The EMA launched a evaluation final month however stated it remained of the opinion that “the advantages of the vaccine in stopping Covid-19 outweigh the dangers of unintended effects”, reported Euronews.